Kiniksa Pharmaceuticals Ltd. Class A Forecast, price target & analysts
Kiniksa Pharmaceuticals Ltd. Class A Target price 2026 - Analyst rating & recommendation
Kiniksa Pharmaceuticals Ltd. Class A Classifications & Recommendation
Kiniksa Pharmaceuticals Ltd. Class A Price Target
| Target Price | $99.96 |
| Price | $75.08 |
| Potential |
33.14%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Kiniksa Pharmaceuticals Ltd. Class A 2027 .
The average Kiniksa Pharmaceuticals Ltd. Class A target price is $99.96.
This is
33.14%
register free of charge
$113.40
51.04%
register free of charge
$87.87
17.04%
register free of charge
|
|
| A rating was issued by 14 analysts: 13 Analysts recommend Kiniksa Pharmaceuticals Ltd. Class A to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Kiniksa Pharmaceuticals Ltd. Class A stock has an average upside potential 2027 of
33.14%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 677.56 | 1,014.00 |
| 60.09% | 49.65% | |
| EBITDA Margin | 11.63% | 16.22% |
| 212.05% | 39.50% | |
| Net Margin | 8.71% | 8.99% |
| 185.35% | 3.22% |
10 Analysts have issued a sales forecast Kiniksa Pharmaceuticals Ltd. Class A 2026 . The average Kiniksa Pharmaceuticals Ltd. Class A sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Kiniksa Pharmaceuticals Ltd. Class A EBITDA forecast 2026. The average Kiniksa Pharmaceuticals Ltd. Class A EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Kiniksa Pharmaceuticals Ltd. Class A Analysts have issued a net profit forecast 2026. The average Kiniksa Pharmaceuticals Ltd. Class A net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.75 | 1.17 |
| 225.00% | 56.00% | |
| P/E | 64.23 | |
| EV/Sales | 5.26 |
10 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast for earnings per share. The average Kiniksa Pharmaceuticals Ltd. Class A EPS is
This results in the following potential growth metrics and future valuations:
Kiniksa Pharmaceuticals Ltd. Class A...
Current Kiniksa Pharmaceuticals Ltd. Class A Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Jul 30 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Jul 29 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Jul 29 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Jul 29 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Jul 29 2026 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Jul 23 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Jul 13 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Jul 30 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Jul 29 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Jul 29 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Jul 29 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Jul 29 2026 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Jul 23 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Jul 13 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
